Document:

alks-ex101_85.htm

Exhibit 10.1

 

	

	
 
	
 

 

 

 

 

 

 

Biogen Swiss Manufacturing GmbH

Neuhofstrasse 30

6340 Baar

Switzerland

 

 

31 January 2019

 

 

Re: Amendment to License and Collaboration Agreement

 

 

Dear Sirs

 

We refer to the License and Collaboration Agreement dated 27 November 2017 between Alkermes Pharma Ireland Limited (“Alkermes”) and Biogen Swiss Manufacturing GmBH (“Biogen”) (the “License”).  This letter is supplemental to the License and amends Section 5.1.2 thereto as set out below.

 

Capitalised terms used in this letter shall have the same meaning as set out in the License. 

 

	
 
	
1.
	
Alkermes and Biogen hereby agree that, with effect from the date this letter is signed by Biogen, the six (6) month period within which Alkermes and Biogen are to negotiate the terms of a commercial supply agreement for the Manufacture of Commercial Supplies shall be extended by a further period of two (2) months and Section 5.1.2 of the License is hereby amended accordingly.

 

	
 
	
2.
	
Notwithstanding Section 14.3 of the License, this letter, the License and the Exhibits referred to therein represent the entire agreement between the Parties regarding their subject matter.

 

	
 
	
3.
	
This letter shall be governed by and construed in accordance with the laws of the State of New York (other than its choice of law principles).

 

To indicate Biogen’s agreement to the above terms, please arrange for this letter to be executed by a duly authorised officer of Biogen where indicated below and return to us.

Yours faithfully 

	
/s/ Kevin Brady
	
 
	
 

	
Alkermes Pharma Ireland Limited
	
 
	
 

Alkermes Pharma Ireland Limited. Registered in Ireland (company number 448848). Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6. Directors: Shane Cooke – Chairman, Richard Pops (USA), Blair Jackson (USA), Kevin Brady, Richie Paul

 

			
	

	
 
	
 

 

 

 

 

Agreed and Accepted

 

BIOGEN SWISS MANUFACTURING GMBH  

	
By:
	
/s/ Fabrice Etienne
	
 
	
 

	
(Signature)
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
Name:
	
FABRICE ETIENNE
	
 
	
 

	
 
	
 
	
 
	
 

	
Title:
	
Head of External Manufacturing
	
 
	
 

	
 
	
 
	
 
	
 

	
Date:
	
31 Jan 2019
	
 
	
 

 

 

 

 

Alkermes Pharma Ireland Limited. Registered in Ireland (company number 448848). Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6. Directors: Shane Cooke – Chairman, Richard Pops (USA), Blair Jackson (USA), Kevin Brady, Richie PaulExhibit 4.7

 

THIS
COMMON STOCK PURCHASE WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS COMMON STOCK PURCHASE WARRANT HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE
HARBOR PROVISION.

 

COMMON
STOCK PURCHASE WARRANT

A-1

 

VOID
AFTER 5:00 P.M., EASTERN TIME ON November 10, 2022

 

For
the Purchase of Twenty Two and One-Half Percent (22.5%) of the

Issued and Outstanding Shares of Common Stock, $0.001 Value

of 

MyDx, Inc. 

a Nevada corporation

 

THIS
CERTIFIES THAT, for value received, Mr. Cannabis, Inc., a California corporation (the “Holder”), as registered
owner of this Common Stock Purchase Warrant (“Warrant”), is, subject to the Exercise Restrictions (as defined
below), entitled to, at any time at or before the Expiration Date (as defined below), but not thereafter, to subscribe for,
purchase and receive twenty two and one half percent (22.5%) of the common shares issued and outstanding at the time of the
first notice of exercise given by the Holder, of the fully paid and non assessable shares of common stock (the
“Common Stock”), of MyDx, Inc., a Nevada corporation (the “Company”), at $.001 per share (the
“Exercise Price”), upon presentation and surrender of this Warrant and upon payment by cashier’s check,
wire transfer or credit of the Exercise Price for
such Common Stock to the Company at the principal office of the Company; provided, however, that upon the occurrence of any
of the events specified in the Statement of Rights of Warrant Holder, a copy of which is attached as Annex 1 hereto, and by
this reference made a part hereof, the rights granted by this Warrant shall be adjusted as therein specified.

 

Upon
exercise of this Warrant, the form of election must be duly executed and the instructions for registration of the Shares acquired
by such exercise must be completed.

 

The term Expiration
Date (the “Expiration Date”) means the earliest of (i) the third anniversary of the date hereof, (ii) immediately
prior to the sale of all of substantially all of the Company’s assets, or (iii) immediately
prior to a merger or consolidation in which securities possessing more than 50% of the total combined voting power of
the Company’s outstanding securities are transferred to a person or persons different
from the persons holding those securities immediately prior to such transaction; provided, that the Company shall give
notice to the Holder at least 30 days prior to the events set forth in clauses (i), (ii) and (iii) above.

 

If
the subscription rights represented hereby are not exercised at or before the Expiration Date, this Warrant shall become void,
and all rights represented hereby shall cease and expire.

 

     

     

    

 

Subject to the
exercise restrictions set forth in Section 3.3 of Annex 1 to this Warrant, attached hereto
(the “Exercise Restrictions”), this Warrant may be exercised in accordance with its terms in whole or in part.
In the event of the exercise or assignment hereof in part only, the Company shall cause to be delivered to the Holder a new
Warrant of like tenor to this Warrant in the name of the Holder, evidencing the right of the Holder to purchase the number of
Shares purchasable hereunder as to which this Warrant has not been exercised or assigned.

 

In
no event shall this Warrant (or the Shares issuable, upon full or partial exercise hereof) be offered or sold except in conformity
with the Securities Act of 1933; as amended.

 

COMMON
STOCK PURCHASE WARRANT A-1 

SIGNATURE PAGE

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be signed by its duly authorized officer this November 10, 2018.

 

	 	MyDx,
    Inc.
	 	 	 
	 	By:	/s/ Daniel Yazbeck
	 	 	Daniel Yazbeck
	 	 	Chief Executive Officer

 

    2

     

    

 

NOTICE
OF EXERCISE

 

	TO:	MYDX,
INC.

 

(1)          The undersigned hereby elects to purchase ___________ Warrant Shares of the Company pursuant to the terms of the attached
Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.

 

(2)          Payment
shall take the form of (check applicable box):

 

1.          
☐ in lawful money of the United States; or

 

2.          
☐ the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section 3.4,
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in Section 3.4.

 

(3)          Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as
is specified below:

 

___________________________________ 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

___________________________________ 

 

___________________________________ 

 

___________________________________ 

 

(4) Accredited
Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name: _____________________________________________

Date:  _____________________________________________

 

NOTICE:          
The signature to exercise must correspond with the
name upon the face of the Warrant in every particular without alteration or enlargement or any change whatsoever.

 

    3

     

    

 

Form to be used to transfer Warrants: 

 

	TO:	MyDx, Inc.	 
	 	 	 
	DATE:	 	 

 

FOR VALUE RECEIVED,
______________________________ hereby irrevocably sells, assigns and transfers unto____________________________ the
attached Warrant, together with all right, title and interest therein, and does hereby irrevocably constitute and appoint the
Manager or the Secretary of the Company attorney, to transfer said Warrant Certificate on the books of the company with the
full power of substitution in the premises.

 

	Name of Holder:	 	 
	 	 	 
	Signature:	 	 
	 	 	 
	 	 	 
	 	(Address)	 

 

Form to be used for partial assignment of Warrants: 

 

FOR VALUE RECEIVED,
____________________________ hereby sells, assigns and transfers unto ________________ the right to
purchase__________ shares of Warrant Shares evidenced by the within Warrant together with all right, title and interest
therein, and does hereby irrevocably constitute and appoint the Secretary of the Company attorney, to transfer said Warrant
Certificate on the books of the company with the full power of substitution in the premises.

 

	Name of Holder:	 	 
	 	(Please Print)	 
	 	 	 
	Signature:	 	 
	 	 	 
	 	 	 
	 	(Address)	 

 

    4

     

    

 

ANNEX 1 TO MyDx, INC.

COMMON STOCK PURCHASE WARRANT A-1

 

STATEMENT OF RIGHTS OF WARRANT HOLDER

 

1. Exercise of Warrant. Subject to the exercise restrictions set forth in Section 3.3 below, this Warrant may be exercised in whole or in part at
any time at or before the Expiration Date (as defined in the Warrant), by presentation and surrender hereof to the Company, with
the Exercise Form annexed hereto duly executed and accompanied by payment to the Company of an amount of consideration therefor
equal to the Warrant Price in effect on the date of such exercise multiplied by the number of shares of Warrant Shares with respect
to which this Warrant is then being exercised, payable at such Holder’s election by wire transfer to an account designated by
the Company, by cashless exercise in accordance with the provisions of Section 3.4, but only when a registration statement under
the Securities Act providing for the resale of the Warrant Shares is not then in effect, or by a combination of the foregoing
methods of payment selected by the Holder of this Warrant. If this Warrant should be exercised in part only, the Company shall,
upon surrender of this Warrant for cancellation, execute and deliver a new Warrant evidencing the right of the Holder to purchase
the balance of the shares purchasable hereunder. Upon receipt by the Company of this Warrant and the Exercise Price at the office
or agency of the Company, in proper form for exercise, the Holder shall be deemed to be the holder of record of the common stock
issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates
representing such common stock shall not then be actually delivered to the Holder.

 

2. Rights of the
Holder. The Holder shall not, by virtue hereof, be entitled to any rights of a member in the Company, either at law or equity,
and the rights of the Holder are limited to those expressed in the Warrant and are not enforceable against the Company except
to the extent set forth herein.

 

3. Adjustment in
Number of Shares and Certain Exercise Restrictions.

 

3.1 Adjustment
for Reclassifications. In case at any time or from time to time after November 10, 2018 (“Issue Date”)
the holders of the Common Stock of the Company (or any shares or other securities at the time receivable upon the exercise of
this Warrant) shall have received, or, on or after the record date fixed for the determination of eligible members, shall
have become entitled to receive, without payment therefore, other or additional shares or other securities or property (other
than cash) by way of share-split, spinoff, reclassification, combination of shares or similar corporate rearrangement
(exclusive of any dividend of its or any subsidiary’s shares), then and in each such case, the Holder of this Warrant,
upon the exercise hereof as provided in Section 1, shall be entitled to receive the amount of securities and property which
such Holder would hold on the date of such exercise if on the Issue Date he had been the holder of record of the number of
common stock shares of the Company called for on the face of this Warrant and had thereafter, during the period from the
Issue Date, to and including the date of such exercise, retained such shares and/or all other or additional securities and
property receivable by him as aforesaid during such period, giving effect to all adjustments called for during such
period.

 

    5

     

    

 

3.2 Adjustment
for Reorganization, Consolidation, Merger. In case of any reorganization of the Company (or any other company the securities
of which are at the time receivable on the exercise of this Warrant) after the Issue Date, or in case, after such date, the Company
(or any such other company) shall consolidate with or merge into another company or convey all, or substantially all, of its assets
to another company, then and in each such case the Holder of this Warrant, upon the exercise hereof as provided in Section 1 at
any time after the consummation of such reorganization, consolidation, merger or conveyance, shall be entitled to receive, in
lieu of the securities and property receivable upon the exercise of this Warrant prior to such consummation, the securities or
property to which such Holder would be entitled had the Holder exercised this Warrant immediately prior thereto, all subject to
further adjustment as provided herein; in each such case, the terms of this Warrant shall be applicable to the shares or other
securities or property receivable upon the exercise of this Warrant after such consummation.

 

3.3 Exercise
Restrictions. For so long as the Holder is Mr. Cannabis and the Consulting Agreement between Mr. Cannabis and the Company
has not been terminated, the Holder shall have the right to exercise 1/36th of the shares of Common Stock per
month from the Issue Date (i.e., 0.625% of the shares of Common Stock shall be exercisable each month); provided, however,
completion of the following milestones, with such completion to be in the sole judgment of the majority of the members of
the Company’s Board of Directors (the “Board”), shall further accelerate the Holder’s exercise
schedule based on the percentages outlined below:

 

(i)
Complete gross fundraising of $1,000,000.00 USD or more of capital for the Company in one closing -  Immediate right to
exercise an additional 5% of the shares of Common Stock;

 

(ii) Complete
gross fundraising of $5,000,000.00 USD or more of capital for the Company in one closing (at which time 50% of the series A super
voting shares will be assigned to Holder) - Immediate right to exercise an additional 5% of the shares of Common Stock;

 

(iii) Complete
fundraising of $10,000,000.00 USD or more of growth capital for the Company in one closing - Immediate right to exercise 100% of
the shares of Common Stock;

 

(iv) Upon
achievement of $1,000,000.00 in gross annualized revenue for MyDx or an increase of market value of a 2x or greater sustained for
a minimum of two full weeks or 10 market trading days - Immediate right to exercise an additional 5% of the shares of Common Stock;

 

(v) Complete the
Reverse Split for the Company’s OTC Stock at a $2-$4 per share market price and a closing share price of $1 or more for
at least a period of 30 consecutive days - Immediate right to exercise an additional 5% of the shares of Common Stock;

 

(vi) Complete
a cross listing process of the Company stock into a Canadian exchange - Immediate right to exercise an additional 5% of the shares
of Common Stock;

 

(vii) Complete
the successful transition of the management and the full time operations of MyDx from Mr. Daniel Yazbeck to the Mr. Cannabis Team,
marked by the signing of an agreement and announcement to the public markets via a press release - Immediate right to exercise
an additional 1% of the shares of Common Stock;

 

(viii) Launch
the EcoSmartPen with the MyDx Brand to fulfill the pre-existing orders - Immediate right to exercise an additional 1% of the
shares of Common Stock;

 

(ix) Launch
the EcoSmartPen with the Mr. Cannabis brand - Immediate right to exercise an additional 1% of the shares of Common Stock;

 

(x) Launch
the EcoSmartPen with a reputable brand (in the sole judgment of the majority of the members of the Board that has at least $500,000.00
in existing gross sales annualized revenue - Immediate right to exercise an additional 1% of the shares of Common Stock;

 

    6

     

    

 

(xi) Onboard a major influencer (in the sole judgment of the majority of the members of the Board) who agrees to help
promote the MyDx brand, products and services - Immediate right to exercise an additional 1% of the shares of Common Stock;

 

(xii) Recruit
a reputable head (in the sole judgment of the majority of the members of the Board) of the scientific board of advisors for MyDx
who can work with the MyDx team to unlock the potential value of the MyDx current and future Database and optimize it to address
the needs of the pharmaceutical industry - Immediate right to exercise an additional 1% of the shares of Common Stock;

 

(xiii) Recruit a
head of the mobile application development for MyDx - Immediate right to exercise an additional 1% of the shares of Common
Stock;

 

(xiv) Complete
an updated diligence packet of materials for MyDx fundraising, including new and updated financial modelling, new investors
presentation, and a well organized (in the sole judgment of the majority of the members of the Board) cloud based investors
diligence folder with all needed fundraising materials/information - Immediate right to exercise an additional 1% of the
shares of Common Stock;

 

(xv) Secure a credit
line for MyDx in excess of $3,000,000.00 with a discount to market of no more than 20% - Immediate right to exercise an additional
1% of the shares of Common Stock;

 

(xvi) Recruit
and onboard a reputable (in the sole judgment of the majority of the members of the Board) investors relations team to help
ensure the success of the MyDx stock - Immediate right to exercise an additional 1% of the shares of Common Stock; or

 

(xvii) Notwithstanding anything
to the contrary set forth in this Warrant, at no time may a Holder of this Warrant exercise this Warrant if the number of shares
of Common Stock to be issued pursuant to such exercise would exceed, when aggregated with all other shares of Common Stock owned
by such Holder at such time, the number of shares of Common Stock which would result in such Holder beneficially owning (as determined
in accordance with Section 13(d) of the Exchange Act and the rules thereunder) in excess of 4.99% of the then issued and outstanding
shares of Common Stock; provided, however, that upon a holder of this Warrant providing the Company with sixty-one (61) days notice
that such Holder would like to waive this Section 3 (xvii) will be of no force or effect with regard to all or a portion of the
Warrant referenced in the a waiver notice; provided, further, that this provision shall be of no further force or effect during
the sixty-one (61) days immediately preceding the expiration of the term of this Warrant.

 

3.4 Cashless
Exercise. Notwithstanding any provisions herein to the contrary and commencing one year following the original
issue date, if there is no effective Registration Statement registering, or no current prospectus available for, the resale
of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such  time by means of
a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the
quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A)
= the closing share price on the trading day immediately preceding the date on which Holder elects to exercise this Warrant
by means of a “cashless exercise,” as set forth in the applicable Notice of Exercise;

 

(B) = the Exercise Price of this Warrant, as adjusted
hereunder; and

 

(X) = the number of
Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.

 

3.5 Adjustment
in Exercise Price. Under no circumstances shall the Exercise Price of the Warrant change. Therefore, in the case of a
reverse stock split or recapitalization or any other event, subsequent to any such event, the Exercise Price shall remain
$.001.

 

    7

     

    

 

4. Notices to
Warrant Holders. So long as this Warrant shall be outstanding and unexercised if the Company shall take any action which would
trigger an adjustment (as set forth in Section 3), then, in any such case, the Company shall cause to be delivered to the Holder,
at least ten days prior to the date specified in (x) or (y) below, as the case may be, notice containing a brief description of
the proposed action and stating the date on which (x) a record is to be taken for the purpose of such dividend, distribution or
rights, or (y) such reclassification, reorganization, consolidation, merger, conveyance; lease, dissolution, liquidation or winding
up is to take place and the date, if any, is to be fixed, as of which the holders of Common Stock of record shall be entitled
to exchange their common stock for securities or other property deliverable upon such reclassification, reorganization, consolidation,
merger, conveyance, dissolution, liquidation or winding up.

 

5. Officer’s
Certificate. Whenever the number of common stock issuable upon exercise of this Warrant or the Exercise Price shall
be adjusted as required by the provisions hereof, the Company shall forthwith file in the custody of its Secretary or
an Assistant Secretary at its principal office, and with its stock transfer agent, if any, an officer’s
certificate showing the adjusted number of common stock or Exercise Price determined as herein provided and setting forth in
reasonable detail the facts requiring such adjustment. Each such officer’s certificate shall be made available at all
reasonable times for inspection by the Holder and the Company shall, forthwith after each such adjustment, deliver a copy of
such certificate to the Holder. Such certificate shall be conclusive as to the correctness of such adjustment.

 

6. Restrictions
on Transfer. The Holder of this Warrant, by acceptance thereof; agrees that, absent an effective registration statement,
under the Securities Act of 1933 (the “Act”), covering the disposition of this Warrant or the Common Stock issued
or issuable upon exercise hereof, such Holder will not sell or transfer any or all of this Warrant or such Common Stock
without first providing the Company with an opinion of counsel reasonably satisfactory to the Company to the effect that such
sale or transfer will be exempt from the registration and prospectus delivery requirements of the Act. The certificates
evidencing the Warrant and Common Stock which will be delivered to such Holder by the Company shall bear substantially the
following legend:

 

THE SECURITIES EVIDENCED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ISSUED IN RELIANCE UPON AN
EXEMPTION FROM THE REQUIREMENTS FOR SUCH REGISTRATION FOR NONPUBLIC OFFERINGS. ACCORDINGLY, THE SALE, TRANSFER. PLEDGE, HYPOTHECATION
OR OTHER DISPOSITION OF THE SECURITIES EVIDENCED HEREBY OR ANY PORTION THEREOF OR INTEREST THEREIN MAY NOT BE ACCOMPLISHED IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THAT ACT OR AN OPINION OF COUNSEL TO THE HOLDER OF THE SECURITIES (UNLESS
THE COMPANY DETERMINES IN ITS SOLE DISCRETION TO USE ITS OWN COUNSEL), WITH ANY SUCH COUNSEL AND OPINION OF COUNSEL TO BE REASONABLY
ACCEPTABLE TO THE ISSUER, TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED.

 

Each Holder of this Warrant, at the time
all or a portion of such Warrant is exercised, agrees to make such written representations to the Company as counsel for the Company
may reasonably request, in order that the Company may be reasonably satisfied that such exercise of the Warrant and consequent
issuance of Common Stock will not violate the registration and prospectus delivery requirements of the Act, or other applicable
state securities laws.

 

    8

     

    

 

7. Piggyback
Registration Rights. If, at any time after the Issue Date and expiring on the Expiration Date, the Company proposes to register
any of its securities under the Act either for its own account or for the account of others, in connection with the public offering
of such equity securities solely for cash, on a registration form that would also permit the registration of the common stock
issuable upon exercise of this Warrant (“Warrant Shares)”, the Company shall promptly give the Holder written notice
of such proposal. Within thirty (30) days after the notice is given, the Holder shall give notice as to the number of Warrant
Shares, if any, which have vested and which the Holder requests be registered simultaneously with such registration by the Company.
The Company shall use its best efforts to include such Warrant Shares in such registration statement (or in a separate registration
statement concurrently filed) which the Holder requests to be so included and to cause such registration statement to become effective
with respect to such shares in accordance with the registration procedures set forth in Section 8 hereof. If at any time after
giving written notice of its intention to register equity securities and before the effectiveness of the registration statement
filed in connection with such registration, the Company determines for any reason either not to effect such registration or to
delay such registration, the Company may, at its election, by delivery of written notice to the Holder, (i) in the case of a determination
not to effect registration, relieve itself of a reasonably necessary portion of its obligation to register the Warrant Shares
under this Section 7 in connection with such registration, or (ii) in the case of a determination to delay registration, delay
the registration of the Warrant Shares under this Section 7 for the same period as the delay in the registration of such other
equity securities. Each Holder of Warrant Shares requesting inclusion in a registration pursuant to this Section 7 may, at any
time before the effective date of the registration statement relating to such registration, revoke such request by delivering
written notice of such revocation to the Company (which notice shall be effective only upon receipt by the Company); provided, however, that if the Company, in consultation with its financial and legal advisors, determines that such revocation would
require a recirculation of the prospectus contained in the registration statement, then such Holder of Warrant Shares shall have
no right to revoke its request.

 

8. Expenses and
Procedures.

 

(A) Expenses of
Registration. All registration expenses (exclusive of underwriting discounts and commissions) shall be borne by the Company;
provided, however, that if a Holder revokes a registration request pursuant to the last sentence of Section 7, the registration
expenses in connection with such revoked registration shall be borne by such Holder. Each Holder of Warrant Shares shall bear
all underwriting discounts, selling commissions, sales concessions and similar expenses applicable to the sale of the Warrant
Shares sold by such Holder.

 

(B) Registration
Procedures. In the case of the registration, qualification or compliance effected by the Company pursuant to Section 7 hereof,
the Company will keep the Holders of Warrant Shares advised as to the initiation of registration, qualification and compliance
and as to the completion thereof. At its expense, the Company will furnish such number of prospectuses and other documents incident
thereto as the Holders or underwriters from time to time may reasonably request.

 

    9

     

    

 

(C) Information. The Company may require each seller of Warrant Shares as to which any registration
is being effected to furnish such information regarding the distribution of such Warrant Shares as the Company may from time to
time reasonably request and the Company may exclude from such registration the Warrant Shares of any seller who unreasonably fails
to furnish such information after receiving such request.

 

(D) Blue
Sky. The Company will, as expeditiously as possible, use its best efforts to register or qualify the Warrant Shares covered
by a registration statement at the expense of the Company in such jurisdictions as the holders of such Warrant Shares or, in the
case of an underwritten public offering, the managing underwriter shall reasonably request at the expense of the Holders of the
Warrant Shares being registered provided that the Company shall not be required in connection with any such registration or qualification
or as a condition thereto to qualify to do business in any jurisdiction where it is not so qualified or to take any action which
would subject it to taxation or service of process in any jurisdiction where it is not otherwise subject to such taxation or service
of process.

 

(E) Notification
of Material Events. The Company will, as expeditiously as possible, immediately notify each holder of Warrant Shares under
a registration statement, at any time when a prospectus relating thereto is required to be delivered under the Act, of the happening
of any event as a result of which the prospectus contained in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements
therein not misleading in the light of the circumstances then existing and, as expeditiously as possible, amend or supplement such
prospectus to eliminate the untrue statement or the omission.

 

9. Indemnification.

 

(A) Indemnification by Company. The Company shall, without
limitation as to time, indemnify and hold harmless, to the full extent permitted by law, each holder of Warrant Shares, its
officers, directors, agents and employees, each person who controls such holder (within the meaning of Section 15 of the Act
or Section 20 of the Securities Exchange Act of 1934, as amended, hereinafter the “Exchange Act”) and the
officers, directors, agents or employees of any such controlling person, from and against all losses, claims, damages,
liabilities, costs (including, without limitation, all reasonable attorneys’ fees) and expenses
(collectively “Loss” or “Losses”), as incurred, arising out of or based upon any untrue statement or
alleged untrue statement of a material fact contained in any registration statement, prospectus or preliminary prospectus or
any amendment or supplement thereto, or arising out of or based upon any omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein in light of the circumstances under which they were
made (in the case of any prospectus) not misleading, except insofar as the same are based solely upon information furnished
to the Company by such holder for use therein; provided, however, that the Company shall not be liable in any such case to
the extent that any such Loss arises out of or is based upon an untrue statement or alleged untrue statement or omission made
in any preliminary prospectus or prospectus if (i) such holder failed to send or deliver a copy of the prospectus
or prospectus supplement with or prior to the delivery of written confirmation of the sale of Warrant Shares and (ii)
the prospectus or prospectus supplement would have corrected such untrue statement or omission. If requested, the Company
shall also indemnify underwriters, selling brokers, dealer managers and similar securities industry professionals
participating in the distribution, their officers, directors, agents and employees and each person who controls such persons
(within the meaning of Section 15 of the Act or Section 20 of the Exchange Act) to the same extent as provided above with
respect to the indemnification of the Holders of Warrant Shares. It is agreed that the indemnity agreement contained in
this Section 9(A) shall not apply to amounts paid in settlement of any such Loss if such settlement is effected without
the consent of the Company (which consent has not been unreasonably withheld).

 

    10

     

    

 

(B) Conduct of Indemnification Proceedings. If any action
or proceeding (including any governmental investigation or inquiry) shall be brought or any claim shall be asserted against
any person entitled to indemnity hereunder (an “Indemnified Party”), such indemnified party shall promptly
notify the party from which such indemnity is sought (the “Indemnifying Party”) in writing, and the indemnifying
party shall assume the defense thereof including the employment of counsel reasonably satisfactory to the indemnified party
and the payment of all fees and expenses incurred in connection with the defense thereof. All such fees and expenses
(including any fees and expenses incurred in connection with investigation or preparing to defend such action or proceeding)
shall be paid to the indemnified party, as incurred, within 20 days of written notice thereof to the indemnifying party;
provided, however, that if, in accordance with this Section 9, the indemnifying party is not liable to the indemnified party,
such fees and expenses shall be returned promptly to the indemnifying party. Any such indemnified party shall have the right
to employ separate counsel in any such action, claim or proceeding and to participate in the defense thereof, but the fees
and expenses of such counsel shall be the expense of such indemnified party unless (a) the indemnifying party has agreed to
pay such fees and expenses, (b) the indemnifying party shall have failed promptly to assume the defense of such action, claim
or proceeding and to employ counsel reasonably satisfactory to the indemnified party in any such action, claim or proceeding,
or (c) the named parties to any such action, claim or proceeding (including any impleaded parties) include both such
indemnified party and the indemnifying party, and such indemnified party shall have been advised by counsel that there may be
one or more legal defenses available to it which are different from or additional to those available to the indemnifying
party (in which case, if such indemnified party notifies the indemnifying party in writing that it elects to employ separate
counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of
such action, claim or proceeding on behalf of such indemnified party, it being understood, however, that the indemnifying
party shall not, in connection with any one such action, claim or proceeding or separate but substantially similar or
related actions, claims or proceedings in the same jurisdiction arising out of the same general allegations or circumstances,
be liable for the reasonable fees and expenses of more than one separate firm of attorneys (together with appropriate
local counsel) at any time for all such indemnified parties, unless in the opinion of counsel for such indemnified party a
conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such
action, claim or proceeding, in which event the indemnifying party shall be obligated to pay the fees and expenses of
such additional counsel or counsels). No indemnifying party will consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the release of such indemnified party from all liability
in respect to such claim or litigation without the written consent (which consent will not be unreasonably withheld) of the
indemnified party. No indemnified party shall consent to entry of any judgment or enter into any settlement without the
written consent (which consent will not be unreasonably withheld) of the indemnifying party from which indemnify or
contribution is sought.

 

    11

     

    

 

(C) Contribution. If the indemnification provided for in
this Section 9 is unavailable to an indemnified party under Section 9(A) or 9(B) hereof (other than by reason of exceptions
provided in those Sections) in respect of any Losses, then each applicable indemnifying party in lieu of indemnifying such
indemnified party shall contribute to the amount paid or payable by such indemnified party as a result of such Losses, in
such proportion as is appropriate to reflect the relative fault of the indemnifying party and indemnified party in connection
with the actions, statements or omissions which resulted in such Losses as well as any other relevant equitable
considerations. The relative fault of such indemnifying party and the indemnified party shall be determined by reference to,
among other things, whether any action in question, including any untrue statement or alleged untrue statement of a material
fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by
such indemnifying party or indemnified party, and the parties’ relative intent, knowledge, access to information
and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result
of any Losses shall be deemed to include, subject to the limitations set forth in Section 9(B), any legal or other fees
or expenses reasonably incurred by such party in connection with any action, suit, claim, investigation or proceeding.
The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 9(C) were
determined by pro rata allocation or by any other method of allocation which does not take into account the equitable
considerations referred to in the immediately preceding paragraph. No person guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.

 

10. Loss
or Mutilation. Upon receipt by the Company of evidence satisfactory to it (in the exercise of reasonable discretion) of the
ownership of and the loss, theft, destruction or mutilation of any Warrant and (in the case of loss, theft or destruction) of indemnity
satisfactory to it (in the exercise of reasonable discretion), and (in the case of mutilation) upon surrender and cancellation
thereof, the Company will execute and deliver in lieu thereof a new Warrant of like tenor.

 

11. Reservation
of Shares. The Company shall at all times reserve and keep available for issue upon the exercise of Warrants such number of
its authorized but unissued common stock as will be sufficient to permit the exercise in full of all outstanding Warrants.

 

12. Notices.
All notices and other communications from the Company to the Holder of this Warrant shall be mailed by first class registered or
certified mail, postage prepaid, to the address furnished to the Company in writing by the last Holder of this Warrant who shall
have furnished an address to the Company in writing.

 

13. Change;
Waiver. Neither this Warrant nor any term hereof may be changed, waived, discharged or terminated orally but only by an instrument
in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought.

 

14. Law
Governing. This Warrant shall be construed and enforced in accordance with and governed by the laws of the State of Nevada.

 

DATED: November 10, 2018

 

	 	MyDx, Inc.
	 	A Nevada corporation
	 	 
	 	By:	/s/ Daniel Yazbeck
	 	 	Daniel Yazbeck
	 	 	Chief Executive Officer

 

 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]